Lv61
1670 积分 2023-12-13 加入
TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
8天前
已完结
Hepatocellular carcinoma
8天前
已完结
LBA35 Camrelizumab (C) plus rivoceranib (R) vs. sorafenib (S) as first-line therapy for unresectable hepatocellular carcinoma (uHCC): A randomized, phase III trial
9天前
已完结
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
9天前
已完结
Immune checkpoint inhibitors in hepatocellular carcinoma: emerging challenges in clinical practice
9天前
已完结
Outcome of patients with HCC and liver dysfunction under immunotherapy: a systematic review and meta-analysis
2个月前
已完结
Hepatocellular Carcinoma
2个月前
已完结
From geroscience to precision geromedicine: Understanding and managing aging
3个月前
已完结
Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial
3个月前
已完结
Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in pts with melanoma who progressed during prior anti–PD-1/PD-L1 therapy (mel prior IO) in all-comer and biomarker-enriched populations
3个月前
已完结
皖公网安备34019202002308
